Economic burden of interstitial lung disease in a commercially insured population with Sjögren syndrome in the United States

BACKGROUND: Patients with Sjögren syndrome (SjS) have substantial cost burden on the health care system; among these patients, those who develop interstitial lung disease (ILD) experience poorer quality of life and have a higher mortality risk. However, the economic burden of ILD has not been docume...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Tsung-Ying, Slejko, Julia F, Davies-Teye, Bernard Bright, Onukwugha, Eberechukwu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372984/
https://www.ncbi.nlm.nih.gov/pubmed/35737860
http://dx.doi.org/10.18553/jmcp.2022.28.7.786

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372984/
https://www.ncbi.nlm.nih.gov/pubmed/35737860
http://dx.doi.org/10.18553/jmcp.2022.28.7.786

Ejemplares similares